Why the study?
Does feature tracking CMR strain analysis distinguish preclinical and overt ARVD/C from control subjects?
Does feature tracking CMR strain analysis distinguish preclinical and overt ARVD/C from control subjects?
FT-CMR subtricuspid strain analysis shows potential for identifying early, preclinical ARVD/C prior to overt disease expression, despite significant intersoftware variability.
May enable preclinical ARVD/C identification; leaves open standardization of feature-tracking software and prospective validation.
Despite large intersoftware variability of FT-CMR derived strain values, all four software methods distinguished overt ARVD/C patients from control subjects by both global and subtricuspid strain values. In the subtricuspid region, one software package distinguished preclinical from control subjects, suggesting the potential to identify early ARVD/C prior to overt disease expression.
No takes yet. Share an insight, caveat, or question.
Bourfiss et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: